Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs Measured

Maves
Graded #102

Higher grade

vs+3.1
Measured
Graded #156

Lower grade

The verdict

Maves takes it — 71.8/100 to 68.7/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with positioning around fat loss, lean muscle, and energy.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMeasured +2
84
86
Dose & formulationMeasured +12
65
77
Clinical oversightMaves +21
76
55
Labs & monitoringMeasured +11
52
63
FulfillmentMaves +20
87
67
Contract termsMaves +14
55
41
Maves · left barMeasured · right bar

The numbers

MetricMavesMeasured
WeighScore71.8/10068.7/100
GradeCC
Scorecard rank#102#156
Semaglutide$99/mo (starting dose, first-month rate, compounded)$119/mo (compounded)
TirzepatideNot disclosed$219/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Maves

Graded #102 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
Measured

Graded #156 · C

FDAWarning letter issued to Better Health Labs, Inc. dba Measured in February 2026. See the FDA warning-letter database.

Strengths

  • Membership includes 1:1 nutrition support and board-certified provider care
  • Both compounded (from $79/mo microdose, $119 semaglutide, $229 tirzepatide) and brand-name Wegovy/Zepbound
  • Insurance or cash-pay options for brand-name medications
  • Oral option available (Wegovy pill); cancel-anytime membership

Where it loses points

  • The headline $79 'GLP-1 Microdose' is a promotional rate off a $99 list price, is filed by the provider under longevity rather than weight loss, and is not a labeled therapeutic dose of either molecule
  • Branded plans are a $49/mo membership with the medication billed separately at $149 to $449/mo
  • The site never states which billing term its 'from' prices assume, though the terms allow monthly, quarterly, semi-annual and annual
  • No state count is published
  • FDA issued Better Health Labs, Inc. dba Measured a warning letter in February 2026; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard